186 related articles for article (PubMed ID: 37893133)
21. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs Correlate with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in a Chinese Population.
Chen J; Zhu J; Wang Z; Yao X; Wu X; Liu F; Zheng W; Li Z; Lin A
Med Sci Monit; 2017 May; 23():2565-2583. PubMed ID: 28550707
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
[TBL] [Abstract][Full Text] [Related]
24. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
25. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
Zanghì A; Manuti V; Serviddio G; D'Amico E; Avolio C
Front Immunol; 2023; 14():1226130. PubMed ID: 37711630
[TBL] [Abstract][Full Text] [Related]
26. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
[TBL] [Abstract][Full Text] [Related]
28. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Muñoz-San Martín M; Gómez I; Quiroga-Varela A; Gonzalez-Del Río M; Robles Cedeño R; Álvarez G; Buxó M; Miguela A; Villar LM; Castillo-Villalba J; Casanova B; Quintana E; Ramió-Torrentà L
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724195
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
30. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
31. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
32. CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders.
Perdaens O; Dang HA; D'Auria L; van Pesch V
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32033981
[TBL] [Abstract][Full Text] [Related]
33. The identification of up-regulated ebv-miR-BHRF1-2-5p targeting MALT1 and ebv-miR-BHRF1-3 in the circulation of patients with multiple sclerosis.
Wang YF; He DD; Liang HW; Yang D; Yue H; Zhang XM; Wang R; Li B; Yang HX; Liu Y; Chen Y; Duan YX; Zhang CY; Chen X; Fu J
Clin Exp Immunol; 2017 Jul; 189(1):120-126. PubMed ID: 28253538
[TBL] [Abstract][Full Text] [Related]
34. miRNA-146a-5p is upregulated in serum and cartilage samples of patients with osteoarthritis.
Skrzypa M; Szala D; Gablo N; Czech J; Pajak J; Kopanska M; Trzeciak M; Gargasz K; Snela S; Zawlik I
Pol Przegl Chir; 2019 Feb; 91(3):1-5. PubMed ID: 31243168
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
36. First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers.
Hromadnikova I; Kotlabova K; Krofta L
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409311
[TBL] [Abstract][Full Text] [Related]
37. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
38. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
39. Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis.
Ye L; Zuo Y; Yang H; Li W; Peng Q; Lu X; Wang G; Shu X
J Immunol Res; 2019; 2019():2927061. PubMed ID: 30915368
[TBL] [Abstract][Full Text] [Related]
40. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
